The leukemia dual-antagonist treatment approach has been shown to be effective. Due to the different conditions of different patients, using the same treatment method, the results may not be the same. Leukemia dual-antibody is mainly for gene mutation, targeted therapy, for example, acute promyelocytic leukemia, can be used all-trans retinoic acid targeted therapy, the role of the RARA gene, as a specific targeting of gene therapy targeting drug effect is better. If the patient is chronic granulocytic leukemia, the treatment of choice for molecular targeted therapy drug imatinib. Patients with CD20+ expression by molecular diagnosis can use rituximab, which is also a targeted therapy drug. The so-called dual-antibody therapy aims to use two targeted drugs at the same time for simultaneous targeted therapy, and this therapy may have better results. Leukemia patients are recommended to standardize the treatment as early as possible under a specialist, the above drugs need to be used under the guidance of a physician, and self-medication is contraindicated.